Related Experiment Videos
Risk factors for development of subclinical hypothyroidism during valproic acid therapy
M A Mikati1, H Tarabay, A Khalil
1Department of Pediatrics, American University of Beirut Medical Center, Beirut, Lebanon. mamikati@aub.edu.lb <mamikati@aub.edu.lb>
The Journal of Pediatrics
|July 24, 2007
Summary
Subclinical hypothyroidism (SCH) affects 25.2% of patients on valproate (VPA) therapy. Younger age, longer VPA treatment duration, and polytherapy increase SCH risk.
Area of Science:
- Neurology
- Endocrinology
- Pharmacology
Background:
- Valproate (VPA) is a widely used antiepileptic drug.
- Subclinical hypothyroidism (SCH) is a condition characterized by elevated thyroid-stimulating hormone (TSH) levels.
- Identifying risk factors for SCH in patients on VPA is crucial for proactive management.
Purpose of the Study:
- To determine the prevalence of subclinical hypothyroidism (SCH) in patients undergoing valproate (VPA) therapy.
- To identify specific risk factors associated with the development of SCH in this patient population.
Main Methods:
- A 2-year prospective study comparing patients on VPA with a control group.
- Screening for SCH (TSH >5 mIU/mL) in both groups.
- Bivariate and multivariate analyses to identify predictors of SCH.
Main Results:
- SCH was diagnosed in 25.2% of VPA-treated patients versus 0% in controls (P < .001).
- Key risk factors identified included younger age (cutoff 3.9 years), treatment duration of 6-24 months or >24 months, and VPA polytherapy.
- Polytherapy with enzyme-inducing agents showed the highest odds ratio for SCH (OR: 6.08).
Conclusions:
- Younger age, co-medication with other antiepileptic drugs, and a VPA treatment duration of 6-24 months are significant risk factors for SCH.
- Targeted screening for SCH in VPA-treated patients with these risk factors is recommended.
Related Concept Videos
01:23Hypothyroidism II: Pathophysiology
Hypothyroidism is a disorder characterized by insufficient production of thyroid hormones, which regulate metabolism, energy balance, and multiple organ systems.TypesHypothyroidism is classified based on the level of dysfunction. Primary hypothyroidism results from intrinsic thyroid gland dysfunction, causing reduced hormone production despite normal or increased stimulation. Secondary hypothyroidism arises from inadequate thyroid-stimulating hormone (TSH) secretion by the pituitary. Tertiary...
01:27Hyperthyroidism II: Pathophysiology
Hyperthyroidism is a hypermetabolic state caused by elevated levels of thyroid hormones, triiodothyronine (T3) and thyroxine (T4). It results from dysregulation at the thyroid, pituitary, or immune system level and affects multiple organ systems.PathophysiologyThe most common cause of hyperthyroidism is Graves’ disease, an autoimmune disorder in which antibodies, specifically thyroid-stimulating antibodies (TSAb), a subtype of TSH receptor antibodies (TRAb), bind to and activate TSH receptors...
01:24Drug Toxicity: Risk factors
Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:28Graves' Disease I: Introduction
Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
01:24Graves Disease II: Pathophysiology
Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...